Advancing a new approach to schizophrenia: TARGETING NEGATIVE SYMPTOMS
At Minerva, we are advancing a first-of-its-kind approach: targeting the disorder’s negative symptoms that can limit how people live, connect and function every day.
Our primary goal: Helping patients re-engage in their lives
Negative symptoms in patients with schizophrenia include loss of motivation, emotional blunting, and social withdrawal and are some of the most debilitating aspects of schizophrenia, yet remain largely unaddressed in current treatments.
Our lead program, roluperidone (MIN-101), is the only investigational medicine to demonstrate improvement in the negative symptoms of schizophrenia in a patient population with stable positive symptoms and impairing negative symptoms.
Breaking through the “glass wall”
Many people with schizophrenia describe their experience as living behind a “glass wall”—present, but unable to fully participate. Our lead program, roluperidone (MIN-101), is currently being studied in a confirmatory Phase 3 trial focused on treating negative symptoms among patients with a lower risk of relapse of positive symptoms.
Driven by what patients have been missing
Our expertise across neuropsychiatry, clinical pharmacology, and CNS drug development is our “how,” while reshaping the schizophrenia treatment landscape is our “why.” At Minerva, we are here because there are many people who have been diagnosed with schizophrenia who do not benefit from the current treatment regimens.
